Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 12, 2003, Pages 3774-3779

  Larabi, Malika ^a   Yardley, Vanessa ^b   Loiseau, Philippe M ^c   Appel, Martine ^a   Legrand, Philippe ^a   Gulik, Annette ^d   Bories, Christian ^c   Croft, Simon L ^b   Barratt, Gillian ^a  

^a UNIV PARIS SUD   (France)

^b UNIVERSITÉ PARIS SUD   (France)

^c CNRS   (France)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; ERYTHROCYTE; FEMALE; HEMOLYSIS; IC 50; LEISHMANIA DONOVANI; LEISHMANIASIS; LETHAL DOSE; LIPID COMPOSITION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

EID: 0345306179     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.12.3774-3779.2003     Document Type: Article

References (46)

1. Al-Abdely, H. M., J. R. Graybill, R. Bocanegra, L. Najvar, E. Montalbo, S. L. Regen, and P. C. Melby. 1998. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. Antimicrob. Agents Chemother. 42:2542-2548.
2. Alving, C. R. 1983. Delivery of liposome-encapsulated drugs to macrophages. Pharmacotherapy 22:407-424.
3. Barwicz, J., I. Gruda, and P. Tancrede. 2000. A kinetic study of the oxidation effects of amphotericin B on human low-density lipoproteins. FEBS Lett. 465:83-86.
4. Berman, J. D., R. Badaro, C. P. Thakur, K. M. Wasunna, K. Behbehani, R. Davidson, F. Kuzoe, L. Pang, K. Weerasuriya, and A. D. Bryceson. 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. W. H. O. 76:25-32.
5. Brajtburg, J., W. G. Powderly, G. S. Kobayashi, and G. Medoff. 1990. Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34:183-188.
6. Brajtburg, J., and J. Bolard. 1996. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 9:512-531.
7. Bryceson, A. 2001. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health 6:928-934.
8. Cohen, B. E., H. Ramos, M. Gamargo, and J. Urbina. 1986. The water and ionic permeability induced by polyene antibiotics across plasma membrane vesicles from Leishmania sp. Biochim. Biophys. Acta 860:57-65.
9. Croft, S. L., R. N. Davidson, and E. A. Thornton. 1991. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J. Antimicrob. Chemother. 28(Suppl. B):111-118.
10. Davidson, R. N., S. L. Croft, A. Scott, M. Maini, A. H. Moody, and A. D. Bryceson. 1991. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337:1061-1062.
11. Desjeux, P. 1999. Global control and leishmania HIV co-infection. Clin. Dermatol. 17:317-325.
12. Dietze, R., E. P. Milan, J. D. Berman, M. Grogl, A. Falqueto, T. F. Feitosa, K. G. Luz, F. A. Suassuna, L. A. Marinho, and G. Ksionski. 1993. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion). Clin. Infect. Dis. 17:981-986.
13. Espuelas, S., P. Legrand, P. M. Loiseau, C. Bories, G. Barratt, and J. M. Irache. 2000. In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188. Antimicrob. Agents Chemother. 44:2190-2192.
14. Golenser, J., S. Frankenburg, T. Ehrenfreund, and A. J. Domb. 1999. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob. Agents Chemother. 43:2209-2214.
15. Guerin, P. J., P. Olliaro, S. Sundar, M. Boelaert, S. L. Croft, P. Desjeux, M. K. Wasunna, and A. D. Bryceson. 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2:494-501.
16. Guo, L. S. S., and P. K. Working. 1993. Complexes of amphotericin B and cholesteryl sulfate. J. Liposome Res. 3:437-490.
17. Herwaldt, B. L. 1999. Miltefosine - the long-awaited therapy for visceral leishmaniasis? N. Engl. J. Med. 341:1840-1842.
18. Khoo, S. H., J. Bond, and D. W. Denning. 1994. Administering amphotericin B, a practical approach. J. Antimicrob. Chemother. 33:203-213.
19. Laguna, F., R. Lopez-Velez, F. Pulido, A. Salas, J. Torre-Cisneros, E. Torres, F. J. Medrano, J. Sanz, G. Pico, J. Gomez-Rodrigo, J. Pasquau, J. Alvar, et al. 1999. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. J. Acquir. Immune Defic. Syndr. 13:1063-1069.
20. Lamothe, J. 2001. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis. J. Small Anim. Pract. 42:170-175.
21. Larabi, M., P. Legrand, M. Appel, S. Gil, M. Lepoivre, J. P. Devissaguet, F. Puisieux, and G. Barratt. 2001. Reduction of NO synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers. Antimicrob. Agents Chemother. 45:553-562.
22. Lasic, D. D., and D. Papahadjopoulos. 1998. Medical applications of liposomes. Elsevier, Amsterdam, The Netherlands.
23. Litchfield, J. T., and F. Wilcoxon. 1949. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:99-113.
24. Lockwood, D. N. J. 1998. Commentary: some good news for treatment of visceral leishmaniasis in Bihar. BMJ 316:1205.
25. Loiseau, P. M., and C. Bories. 1999. Recent strategies for the chemotherapy of visceral leishmaniasis. Curr. Opin. Infect. Dis. 12:559-564.
26. Loiseau, P. M., L. Imbertie, C. Bories, D. Betbeder, and M. I. De Miguel. 2002. Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations. Antimicrob. Agents Chemother. 46:1597-1601.
27. Mbongo, N., P. M. Loiseau, M. A. Billion, and M. Robert-Gero. 1998. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42:352-357.
28. Mullen, A. B., K. C. Carter, and A. J. Baillie. 1997. Comparison of the efficacy of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother. 41:2089-2092.
29. Neal, R. A., and S. L. Croft. 1984. An in vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J. Antimicrob. Chemother. 14:463-475.
30. Paul, M., R. Durand, H. Fessi, D. Rivollet, R. Houin, A. Astier, and M. Deniau. 1997. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob. Agents Chemother. 41:1731-1734.
31. Petit, C., V. Yardley, F. Gaboriau, J. Bolard, and S. L. Croft. 1999. Activity of a heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani. Antimicrob. Agents Chemother. 43:390-392.
32. Pintado, V., P. Martin-Rabadan, M. L. Rivera, S. Moreno, and E. Bouza. 2001. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine 80:54-73.
33. Ramos, H., P. C. Saint, J. Bolard, and B. E. Cohen. 1994. Effect of ketoconazole on lethal action of amphotericin B on Leishmania mexicana promastigotes. Antimicrob. Agents Chemother. 38:1079-1084.
34. Ramos, H., E. Valdivieso, M. Gamargo, F. Dagger, and B. E. Cohen. 1996. Amphotericin B kills unicellular leishmaniasis by forming aqueous pores permeable to small cations and anions. J. Membr. Biol. 21:65-75.
35. Sampaio, R. N., and P. D. Marsden. 1997. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Rev. Soc. Bras. Med. Trop. 30:125-128. (In Portuguese.)
36. Soto, J., J. Toledo, P. Gutierrez, R. S. Nicholls, J. Padilla, J. Engel, C. Fischer, A. Voss, and J. Berman. 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33:E57-E61.
37. Stainmesse, S., H. Fessi, J. P. Devissaguet, and F. Puisieux. June 1989. Procédé de préparation de systèmes colloidaux dispersibles de lipides amphiphiles sous forme de liposomes submicroniques. European patent 894018571.
38. Sundar, S., and H. W. Murray. 1996. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J. Infect. Dis. 173:762-765.
39. Sundar, S., A. K. Goyal, D. K. More, M. K. Singh, and H. W. Murray. 1998. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin B-lipid complex. Ann. Trop. Med. Parasitol. 92:755-764.
40. Sundar, S., L. B. Gupta, V. Rastogi, G. Agrawal, and H. W. Murray. 2000. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 94:200-204.
41. Sundar, S., G. Agrawal, M. Rai, M. K. Makharia, and H. W. Murray. 2001. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323:419-422.
42. Swenson, C. E., W. R. Perkins, P. Roberts, I. Ahmad, R. Stevens, D. A. Stevens, and A. S. Janoff. 1998. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob. Agents Chemother. 42:767-771.
43. Thakur, C. P. 2001. A single high dose treatment of kala-azar with AmBisome (amphotericin B lipid complex): a pilot study. Int. J. Antimicrob. Agents 17:67-70.
44. Yardley, V., and S. L. Croft. 1997. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob. Agents Chemother. 41:752-756.
45. Yardley, V., and S. L. Croft. 2000. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents 13:243-248.
46. Zijlstra, E., M. Musa, A. G. Khalil, M. E. Hassan, and M. El-Hassan. 2003. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. 3:87-98.